SelectQuote (SLQT) – Cost Discipline Begins to Pay Off


Thursday, November 05, 2026

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1 Results Exceed Expectations. SelectQuote reported fiscal first-quarter 2027 revenue of $280.0 million, down 14.8% year over year but above our estimate of $270.9 million. The adjusted EBITDA loss narrowed to $17.0 million from $32.1 million in the prior-year period, exceeding our forecast for a $25.4 million loss. The results highlight improving profitability despite continued revenue pressure.

Lower Costs Drive Profitability Improvement. Revenue declined amid lower pharmacy volumes, fewer Medicare Advantage policy sales, and reduced carrier-sponsored payments. However, marketing expenses decreased 25.0%, while improving pharmacy economics helped Healthcare Services adjusted EBITDA increase 55.7% to $11.2 million. In Senior, lower acquisition costs and greater use of internally generated leads narrowed the adj. EBITDA loss to $12.3 million from $21.0 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SelectQuote (SLQT) – Cash Flow Inflection Takes Center Stage


Wednesday, August 26, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q4 profitability improves despite softer revenue. Fiscal fourth quarter revenue declined 7% to $321.7 million from $345.1 million in the prior-year period, while adj. EBITDA increased to $11.9 million from $2.7 million. Operating cash usage also improved sharply to $3.3 million from $37.5 million a year earlier, highlighting the company’s improving cash conversion. 

Healthcare Services emerges as a key earnings driver. Healthcare Services generated Q4 revenue of $193.5 million and adj. EBITDA of $12.1 million, with SelectRx membership of approximately 109,000. Importantly, prescription utilization continues to increase even as membership growth moderates, while the Olathe facility provides capacity for more than 200,000 members and meaningful opportunity for additional operating leverage. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.